Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

May 17, 2022; 98 (20) Resident & Fellow Section

Clinical Reasoning: A 37-Year-Old Man With Involuntary Movements, Gait Disturbance, and Hyperesthesia

Dylan Meng, View ORCID ProfileAseel Alsalem, Christina Zhang, View ORCID ProfileTychicus Chen
First published March 29, 2022, DOI: https://doi.org/10.1212/WNL.0000000000200514
Dylan Meng
From the Department of Medicine (D.M.), University of British Columbia; and Division of Neurology (A.A., C.Z., T.C.), Department of Medicine, University of British Columbia, Vancouver, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aseel Alsalem
From the Department of Medicine (D.M.), University of British Columbia; and Division of Neurology (A.A., C.Z., T.C.), Department of Medicine, University of British Columbia, Vancouver, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Aseel Alsalem
Christina Zhang
From the Department of Medicine (D.M.), University of British Columbia; and Division of Neurology (A.A., C.Z., T.C.), Department of Medicine, University of British Columbia, Vancouver, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tychicus Chen
From the Department of Medicine (D.M.), University of British Columbia; and Division of Neurology (A.A., C.Z., T.C.), Department of Medicine, University of British Columbia, Vancouver, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tychicus Chen
Full PDF
Citation
Clinical Reasoning: A 37-Year-Old Man With Involuntary Movements, Gait Disturbance, and Hyperesthesia
Dylan Meng, Aseel Alsalem, Christina Zhang, Tychicus Chen
Neurology May 2022, 98 (20) 851-855; DOI: 10.1212/WNL.0000000000200514

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
1026

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Section 1

A 37-year-old right-handed Indigenous Canadian man presented with 2.5 years of progressive involuntary movements, gait instability, and hyperesthesia. He complained of constant, involuntary head and trunk movements, severe speech disturbance, dysphagia, blurred vision, and binocular diplopia in all directions. He took no regular medications and drank no alcohol. Medical history was noncontributory. Family history was notable for a great uncle who died in his fifties from an unspecified gait disorder.

On examination, vital signs were normal. MMSE was 28/30, losing points for writing a sentence and copying a figure, largely due to involuntary limb movements. He had leftward square wave jerks on primary gaze, saccadic pursuit, bilateral horizontal gaze-evoked nystagmus, and impaired upgaze. He had significant dysarthria with staccato speech. The remainder of the cranial nerve examination was unremarkable. He had an 8-cm amplitude, 3–4-Hz frequency, rhythmic, oscillatory titubation of the head and trunk with rest and posture as well as a 3-cm amplitude, 3–4-Hz frequency, postural and action (up to 5 Hz) tremor of the hands and feet bilaterally. He had an exaggerated startle response without spontaneous myoclonus. Muscle bulk, tone, and power were otherwise normal without fasciculations. Muscle stretch reflexes were 2+ throughout. He had widespread hyperesthesia throughout his limbs and trunk, which precluded more detailed sensory testing. Coordination testing revealed bilateral, lower more than upper limb dysmetria. He had dysdiadokinesia and uncoordinated fine finger movements bilaterally, right more than left, and severe truncal ataxia when sitting upright that worsened when standing. Gait was broad based with lateropulsion.

Questions for Consideration:

  1. Where does this process localize?

  2. What clinical tests and investigations would you consider?

GO TO SECTION 2

Section 2

The patient presents with a slowly progressive pan-cerebellar syndrome affecting speech, eye movements, and prominent truncal and appendicular ataxia. A pan-cerebellar syndrome is usually caused by infectious or parainfectious processes, immune-mediated, or metabolic etiologies. Figure 1 demonstrates an approach to ataxia in adults. In this case, given the slowly progressive symptoms, the main considerations were genetic, metabolic, or immune-mediated causes, whereas vascular and infectious etiologies were considered less likely. However, diffuse hyperesthesia suggests involvement beyond the cerebellum and may be localized to disruption to any part of the central or peripheral somatosensory pathway.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1 Etiologies of Ataxia in Adults

Further review of systems revealed diffuse pruritus, poor sleep with frequent awakening, alternating constipation and diarrhea, and urinary hesitancy. He described a 20-lb weight loss with no fevers or night sweats. He ate a regular diet and had no toxic environmental exposures.

Complete blood count, basic metabolic panel, thyroid stimulating hormone, vitamin B12, vitamin E, iron profile, urinary copper, tissue transglutaminase IgA, and a rheumatologic panel were unremarkable. MRI of the head without contrast showed isolated, diffuse cerebellar atrophy (Figure 2A-B). A paraneoplastic panel (amphiphysin, Ma2/Ta, CV2.1, Ri, Recoverin, SOX1, Titin, Yo, Hu, GAD65, and Tr/DNER), and bacterial and viral cultures in serum and CSF were negative. Enhanced CT of the chest, abdomen, and pelvis and fluorodeoxyglucose positron emission tomography were negative for malignancy. CSF showed elevated protein and positive oligoclonal banding. Targeted genetic testing was performed for Friedrich ataxia and spinocerebellar ataxias 1, 2, 3, 4, and 6 as these are the most common adult-onset genetic ataxias.1 Testing revealed a heterozygous trinucleotide expansion in the frataxin gene, with a point variation on the other allele.

Figure 2
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2 Initial MRI of the Brain and Repeat MRI of the Brain and Cervical Spine With Contrast 10 Months Later

MRI T2-weighted axial brain (A and B), sagittal cervical spine (C), and T1-weighted sagittal and coronal brain (D) show cerebellar atrophy with prominence of the folia (small arrows). There is marked progression over 10 months (A compared B) and no cord atrophy (C). There was no enhancement with gadolinium in the brain or cervical spine (not shown).

Question for Consideration:

  1. Do these findings explain his symptoms?

  2. What other investigations would you consider?

GO TO SECTION 3

Section 3

The differential diagnosis for diffuse cerebellar atrophy is wide and includes toxin exposure, neurodegenerative disorders, hereditary cerebellar ataxias, paraneoplastic degeneration, and infectious or inflammatory cerebellitis.

Friedreich ataxia (FA) is the most common inherited ataxia and is usually caused by a homozygous GAA trinucleotide expansion in the frataxin (FXN) gene on chromosome 9q13.2. Most patients present before age 20 years, with larger GAA expansions correlating with earlier age at onset and severity.2 Although true heterozygotes are asymptomatic, compound heterozygotes (such as our patient) and those with smaller GAA expansions may present with late-onset Friedreich ataxia (LOFA), typically after age 20 years. LOFA presents similarly to FA, although with milder phenotypes and without characteristic skeletal deformities.2,3 Spinal cord atrophy is typically seen regardless of age at onset, but LOFA may have cerebellar vermian atrophy and fourth ventricular enlargement.2,3 LOFA should be considered in the workup of progressive ataxia in young adults given a high prevalence of carriers, estimated at 1 in 50,000 in Caucasian populations.2

Cases describing cerebellar atrophy have been reported for many neurodegenerative disorders such as Alzheimer disease, amyotrophic lateral sclerosis, frontotemporal dementia, multiple system atrophy, and progressive supranuclear palsy.4 Given the patient's age, preserved cognition, and lack of other hallmark clinical or imaging features, these diagnoses were considered less likely. The patient also had no known exposure to alcohol, medications, or other toxins. Therefore, the primary considerations in this case were hereditary cerebellar ataxias, paraneoplastic cerebellar degeneration, and immune-mediated cerebellitis. The concurrent sensory hyperesthesia and autonomic dysfunction suggested either a systemic process or an additional parallel process.

Repeat MRI of the head and cervical spine with contrast performed 10 months later revealed progression of the diffuse cerebellar atrophy with no significant atrophy of the spinal cord (Figure 2, C–E) and no abnormalities on T2-FLAIR. The inflammatory CSF pattern, systemic symptoms not commonly associated with LOFA, and lack of hallmark imaging findings suggested an alternative or additional diagnosis. The compound heterozygotic variation was considered a variant of uncertain significance, potentially contributing to but not fully explaining the patient's syndrome. Given FA is an untreatable condition, it is important to consider other potentially treatable contributors to his presentation.

Serum autoimmune encephalitis antibody panel was sent, which revealed a high positive titer for anti–dipeptidyl peptidase-like protein 6 (DPPX). The patient was trialed on immunosuppressive therapy for presumed anti-DPPX encephalitis with oral prednisone, IV immunoglobulin (IVIg), and rituximab induction. His exaggerated startle significantly improved. He experienced transient improvement in his involuntary movements and hyperesthesia with each of these treatments but continued to have overall gradual progression of his symptoms. He therefore underwent 5 sessions of plasma exchange (PLEX), which further improved his involuntary movements, pruritus, and hyperesthesia. Truncal and appendicular ataxia mildly improved, but he could still not stand unassisted. There was no improvement in speech. Symptoms remained stable 6 weeks after PLEX, and he is planned for maintenance PLEX and rituximab therapy.

Discussion

A novel cell surface antigen mediated encephalitis was described in 2012, secondary to autoantibodies against dipeptidyl peptidase-like protein 6 (DPPX).5 DPPX is a regulatory subunit of the voltage-gated rapidly inactivating potassium channel Kv4.2. It is important in somatodendritic signal integration and inhibition of back propagation of action potentials. Reduced expression due to autoantibody binding leads to hyperexcitability.6

DPPX is highly expressed in the hippocampus, striatum, cerebellum, and myenteric plexus.5 Patients present with a constellation of symptoms attributable to dysfunction in these areas, including cognitive impairment, movement disorders, cerebellar and brainstem dysfunction, and diarrhea with profound weight loss.7 Abnormal movements described in previous case series include parkinsonism, orobuccolingual dyskinesia,8 tremor, myoclonus, rigidity, and hyperekplexia.5,9 Postural hypotension and sleep disturbances have also been reported.7 Hyperexcitability in the central and peripheral nervous systems are reported to cause seizures,7 pruritus,10 and dysesthesias.8 Patients may occasionally present with a picture similar to progressive encephalomyelitis with rigidity and myoclonus (PERM) or stiff-person syndrome.10

Symptoms typically progress over months to years.11 Diagnosis is often delayed due to nonspecific clinical features and frequently unremarkable neuroimaging.12 Association with neoplastic processes has been reported, particularly B-cell lymphoma.13 CSF analysis may show pleocytosis and increased IgG synthesis rate.5,8 Detection of the autoantibody is diagnostic, with higher sensitivity on cell-based assays than immunofluorescence.12 Treatment consists of immunotherapy. This includes corticosteroids, although maintenance with tacrolimus, rituximab, IVIg and PLEX have also been used.7,8,14

In one review of 53 patients, 48% experienced marked improvement after immunotherapy.7 Cessation of therapy led to relapse of symptoms in 2 of 9 patients in a small case series.7 Delay in treatment initiation may correlate with poorer outcomes,7 as highlighted in a case of a 53-year-old man who began treatment with corticosteroids, PLEX, and rituximab 2 years following symptom onset with relatively poor results. Untreated inflammation over time may lead to irreversible atrophy, which is less likely to respond to immunotherapy, as seen in our case.

This case illustrates the broad approach to a patient with a constellation of symptoms including a pan-cerebellar syndrome. An important takeaway from this case is that premature closure after an initial possible diagnosis may result in missed diagnosis of additional pathology. Although the results of the patient's initial genetic testing potentially contributed to his presentation, it did not fully explain his presentation—particularly with hyperesthesia and systemic symptoms. Therefore, it was important to consider additional diagnoses. This is particularly important when a presumed diagnosis is untreatable and there is clinical uncertainty.

Study Funding

No targeted funding reported.

Disclosure

The authors report no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.

Acknowledgment

The authors thank the patient and his family.

Appendix Authors

Table

Footnotes

  • Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

  • Received November 20, 2021.
  • Accepted in final form February 28, 2022.
  • © 2022 American Academy of Neurology

References

  1. 1.↵
    1. Kuo SH
    . Ataxia. Continuum: Lifelong Learn Neurol. 2019;25(4):1036-1054.
    OpenUrl
  2. 2.↵
    1. Paulus-Andres JA,
    2. Burnett MS
    . Three adult-onset autosomal recessive ataxias what adult neurologists need to know. Neurol Clin Pract. 2021;11(3):256-262.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Klockgether T,
    2. Chamberlain S,
    3. Wüllner U, et al.
    Late-onset Friedreich's ataxia. Molecular genetics, clinical neurophysiology, and magnetic resonance imaging. Arch Neurol. 1993;50(8):803-806.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Gellersen HM,
    2. Guo CC,
    3. O'Callaghan C,
    4. Tan RH,
    5. Sami S,
    6. Hornberger M
    . Cerebellar atrophy in neurodegeneration-a meta-analysis. J Neurol Neurosurg Psychiatry 2017;88(9):780-788.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Boronat A,
    2. Gelfand JM,
    3. Gresa-Arribas N, et al.
    Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels. Ann Neurol. 2013;73(1):120-128.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Piepgras J,
    2. Höltje M,
    3. Michel K, et al.
    Anti-DPPX encephalitis: pathogenic effects of antibodies on gut and brain neurons. Neurology 2015;85(10):890-897.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Xiao J,
    2. Fu P,
    3. Li Z
    . Clinical and imaging analysis to evaluate the response of patients with anti-dppx encephalitis to immunotherapy. 2020. doi: 10.21203/rs.3.rs-104470/v2
    OpenUrlCrossRef
  8. 8.↵
    1. Deuel LM,
    2. Yu CH,
    3. Vaughan CL,
    4. Piquet AL
    . Oro-bucco-lingual dyskinesia, weight loss, and cognitive decline in anti-dppx antibody-mediated encephalitis. Mov Disord Clin Pract. 2020;7(suppl 3):S80–S82.
    OpenUrl
  9. 9.↵
    1. Balint B,
    2. Jarius S,
    3. Nagel S, et al.
    Progressive encephalomyelitis with rigidity and myoclonus: a new variant with DPPX antibodies. Neurology 2014;82(17):1521-1528.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Wijntjes J,
    2. Bechakra M,
    3. Schreurs MWJ,
    4. Jongen JLM,
    5. Koppenaal A,
    6. Titulaer MJ
    . Pruritus in anti-DPPX encephalitis. Neurol Neuroimmunol Neuroinflamm 2018;5(3):e455.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Tobin WO,
    2. Lennon VA,
    3. Komorowski L, et al.
    DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients. Neurology 2014;83(20):1797-1803.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Mbonde AA,
    2. Gritsch D,
    3. Arca K,
    4. Blech B,
    5. McKeon A,
    6. Carter J
    . DPPX autoimmune encephalitis: a short report on two patients presenting with classic features of this rare but treatable disease. Mult Scler Relat Disord. 2021;52:102934.
    OpenUrl
  13. 13.↵
    1. Hara M,
    2. Ariño H,
    3. Petit-Pedrol M, et al.
    DPPX antibody-associated encephalitis: main syndrome and antibody effects. Neurology 2017;88(14):1340-1348.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Ye L,
    2. Schnegelsberg M,
    3. Obermann M
    . Dipeptidyl-peptidase-like protein 6 encephalitis treated with immunotherapy. Proc (Bayl Univ Med Cent) 2020;34(1):114-115.
    OpenUrl

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Section 1
    • Section 2
    • Section 3
    • Discussion
    • Study Funding
    • Disclosure
    • Acknowledgment
    • Appendix Authors
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

  • All Movement Disorders
  • Encephalitis
  • Cerebellum

Alert Me

  • Alert me when eletters are published
Neurology: 99 (1)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise